Guardant Health, Inc. (GH)

Market Cap	12.24B +105.8%
Revenue (ttm)	982.02M +32.9%
Net Income	-416.28M
EPS	-3.32
Shares Out	131.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,146,877
Open	90.09
Previous Close	92.23
Day's Range	88.21 - 95.56
52-Week Range	34.88 - 120.74
Beta	1.65
Analysts	Strong Buy
Price Target	117.80 (+26.26%)
Earnings Date	Feb 19, 2026

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transc...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 2,506
• Stock Exchange: NASDAQ
• Ticker Symbol: GH
• Website: https://guardanthealth.com

Financial Performance

In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.

Analyst Summary

According to 20 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $117.8, which is an increase of 26.26% from the latest price.

Price Target

$117.8

(26.26% upside)

Analyst Consensus: Strong Buy